October is shaping up to be a busy month. We [...]
If you follow SHINE, you probably know about our [...]
CEO and founder Greg Piefer will give an invited presentation at the Wisconsin Entrepreneurs’ Conference in Milwaukee. On Thursday, June 2 at 8:45 a.m., Piefer will present the opening keynote before engaging in discussion with the audience.
JANESVILLE, Wis., May 23, 2022 – SHINE Technologies, LLC (SHINE), a next-generation nuclear technology company, today announced Chris Vessell has joined as General Manager of the Therapeutics Division. In this role, he will be responsible for developing and building the team dedicated to SHINE’s strategy and offerings around non-carrier-added lutetium-177 for cancer therapies.
SHINE, a next-generation nuclear technology company, today announced the appointments of global technology, energy sector and business veterans Holli C. Ladhani and Janet S. Wong to the company’s board of directors.
SHINE to supply n.c.a. Lu-177 for the clinical development of ImaginAb investigational radiopharmaceuticals
SHINE Technologies, LLC (SHINE), a next-generation nuclear technology company, and Telix Pharmaceuticals LTD (Telix), a biopharmaceutical company headquartered in Australia, today announced the signing of a clinical supply agreement that provides Telix with SHINE’s non-carrier-added (n.c.a.) lutetium-177 (Lu-177) for use in the clinical development of potential new therapeutics to treat prostate and kidney cancer.
A leader in nuclear technology obtains funding to produce medical isotopes in Europe and to help meet growing demands to provide diagnostic imaging for life-threatening diseases on a global scale.
SHINE and Department of Energy Sign First-ever Contracts Under Uranium Lease and Take-back Program for Molybdenum-99
Vital medical radioisotope used in over 40,000 medical diagnostic procedures [...]
A test engineer works in SHINE's manufacturing [...]